NCT04796194
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MMR, MSI-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: If patients do not have triple negative breast cancer (TNBC, their tumor must be MSI-H (microsatellite instability-high or deficient mismatch repair (MMR; TNBC Patients must have received at least 2 lines of chemotherapy (in the metastatic setting containing 1 or more of the following agents: doxorubicin, epirubicin, pegylated liposomal doxorubicin, docetaxel, paclitaxel (Taxol, albumin-bound paclitaxel (Abraxane, gemcitabine, vinorelbine, vinblastine, capecitabine (Xeloda, ixabepilone (Ixempra eribulin, platinum; If a patient has a germline BRCA mutation and has received a PARP inhibitor, this will be counted as 1 line of chemotherapy
Exclusions: Patients with known bone-only or brain metastases; Patients who have not progressed after prior anti-PD-1 or anti-PD-L1 therapy (e.g., pembrolizumab/Keytruda or atezolizumab/Tecentriq), alone or in combination with systemic therapy
https://ClinicalTrials.gov/show/NCT04796194